keyword
MENU ▼
Read by QxMD icon Read
search

Chemotherapy neuropathy

keyword
https://www.readbyqxmd.com/read/29929349/neuropathic-cancer-pain-prevalence-pathophysiology-and-management
#1
So Young Yoon, Jeeyoung Oh
Neuropathic cancer pain (NCP) is caused by nerve damage attributable to the cancer per se, and/or treatments including chemotherapy, radiotherapy, and surgery; the prevalence is reported to be as high as 40%. The etiologies of NCP include direct nerve invasion or nerve compression by the cancer, neural toxicity, chemotherapy, and radiotherapy. NCP is subdivided into plexopathy, radiculopathy, and peripheral neuropathies, among several other categories. The clinical characteristics of NCP differ from those of nociceptive pain in terms of both the hypersensitivity symptoms (burning, tingling, and an electrical sensation) and the hyposensitivity symptoms (numbness and muscle weakness)...
June 25, 2018: Korean Journal of Internal Medicine
https://www.readbyqxmd.com/read/29925345/induction-therapy-with-paclitaxel-and-bevacizumab-followed-by-switch-maintenance-therapy-with-eribulin-in-japanese-patients-with-her2-negative-metastatic-breast-cancer-a-multicenter-collaborative-open-label-phase-ii-clinical-study-for-the-sbccsg-35-investigators
#2
Kenichi Inoue, Jun Ninomiya, Tsuyoshi Saito, Kei Kimizuka, Masafumi Kurosumi
BACKGROUND: To examine the efficacy and safety of induction therapy with paclitaxel and bevacizumab followed by switch maintenance therapy with eribulin (ISMT) in Japanese patients with HER2-negative metastatic breast cancer (MBC). METHODS: Patients, who had previously undergone a maximum of 2 regimens of chemotherapy, received 3 cycles of induction therapy with paclitaxel (90 mg/m2 intravenously on days 1, 8, and 15 followed by 1-week drug holiday) and bevacizumab (10 mg/kg intravenously after the completion of paclitaxel administration on days 1 and 15)...
June 20, 2018: BMC Cancer
https://www.readbyqxmd.com/read/29924336/effects-of-cryotherapy-on-objective-and-subjective-symptoms-of-paclitaxel-induced-neuropathy-prospective-self-controlled-trial
#3
Akiko Hanai, Hiroshi Ishiguro, Takashi Sozu, Moe Tsuda, Ikuko Yano, Takayuki Nakagawa, Satoshi Imai, Yoko Hamabe, Masakazu Toi, Hidenori Arai, Tadao Tsuboyama
Background: Chemotherapy-induced peripheral neuropathy (CIPN) is a dose-limiting and disabling side effect of taxane anticancer agents. We prospectively evaluated the efficacy of cryotherapy for CIPN prevention. Methods: Breast cancer patients treated weekly with paclitaxel (80 mg/m2 for one hour) wore frozen gloves and socks on the dominant side for 90 minutes, including the entire duration of drug infusion. Symptoms on the treated sides were compared with those on the untreated (nondominant) sides...
February 1, 2018: Journal of the National Cancer Institute
https://www.readbyqxmd.com/read/29920955/nimotuzumab-combined-with-chemotherapy-as-first-line-treatment-for-advanced-lung-squamous-cell-carcinoma
#4
Xiaoyan Si, Shafei Wu, Hanping Wang, Xiaotong Zhang, Mengzhao Wang, Xuan Zeng, Li Zhang
BACKGROUND: This study was conducted to evaluate the efficacy and safety of nimotuzumab combined with chemotherapy as first-line therapy in advanced lung squamous cell carcinoma (LSCC), and to explore predictive biomarkers of the efficacy of nimotuzumab. METHODS: A retrospective study was conducted of patients with advanced LSCC administered nimotuzumab combined with chemotherapy as first-line therapy from June 2012 to December 2016 at the Department of Respiratory Medicine, Peking Union Medical College Hospital...
June 19, 2018: Thoracic Cancer
https://www.readbyqxmd.com/read/29908147/neurofilament-light-chain-as-disease-biomarker-in-a-rodent-model-of-chemotherapy-induced-peripheral-neuropathy
#5
Cristina Meregalli, Giulia Fumagalli, Paola Alberti, Annalisa Canta, Valentina Alda Carozzi, Alessia Chiorazzi, Laura Monza, Eleonora Pozzi, Åsa Sandelius, Kaj Blennow, Henrik Zetterberg, Paola Marmiroli, Guido Cavaletti
The objective of this study is to test the feasibility of using serum neurofilament light chain (NfL) as a disease biomarker in Chemotherapy Induced Peripheral Neuropathy (CIPN) since this easy accessible biological test may have a large impact on clinical management and safety of cancer patients. We performed this preclinical study using a well-characterized rat model based on repeated administration of the cytostatic drug vincristine (VCR, 0.2 mg/kg intravenously via the tail vein once/week for 4 times)...
June 13, 2018: Experimental Neurology
https://www.readbyqxmd.com/read/29895438/phase-2-study-of-dose-dense-doxorubicin-and-cyclophosphamide-followed-by-eribulin-mesylate-with-or-without-prophylactic-growth-factor-for-adjuvant-treatment-of-early-stage-human-epidermal-growth-factor-receptor-2-negative-breast-cancer
#6
Karen A Cadoo, Peter A Kaufman, Andrew D Seidman, Cassandra Chang, Dongyuan Xing, Tiffany A Traina
BACKGROUND: Eribulin has significantly improved overall survival for patients with metastatic breast cancer who received ≥ 2 prior chemotherapy regimens for advanced disease. This trial assessed eribulin as adjuvant therapy for patients with early-stage breast cancer. PATIENTS AND METHODS: Patients with human epidermal growth factor receptor 2-negative, stage I to III breast cancer received doxorubicin 60 mg/m2 and cyclophosphamide 600 mg/m2 provided intravenously on day 1 of each 14-day cycle for 4 cycles, with pegfilgrastim on day 2, followed by 4 cycles of eribulin mesylate 1...
April 7, 2018: Clinical Breast Cancer
https://www.readbyqxmd.com/read/29892554/incident-adverse-events-following-therapy-for-acute-promyelocytic-leukemia
#7
Peter Geon Kim, Kelly Bridgham, Evan C Chen, Mahesh K Vidula, Olga Pozdnyakova, Andrew M Brunner, Amir T Fathi
The use of all-trans retinoic acid (ATRA) combined with arsenic trioxide (ATO) with or without cytotoxic chemotherapy is highly effective in acute promyelocytic leukemia (APL) but incident chronic adverse events (AEs) after initiation of therapy are not well understood. We retrospectively analyzed adult patients with newly diagnosed APL from 2004 through 2014 to identify incident AEs following treatment and contributing risk factors. Cardiac and neurologic AEs were more common and characterized in detail. Cardiac AEs such as the development of coronary artery disease (CAD), arrhythmias, and heart failure had a cumulative incidence of 6...
2018: Leukemia Research Reports
https://www.readbyqxmd.com/read/29889605/integrative-therapies-during-and-after-breast-cancer-treatment-asco-endorsement-of-the-sio-clinical-practice-guideline
#8
Gary H Lyman, Heather Greenlee, Kari Bohlke, Ting Bao, Angela M DeMichele, Gary E Deng, Judith M Fouladbakhsh, Brigitte Gil, Dawn L Hershman, Sami Mansfield, Dawn M Mussallem, Karen M Mustian, Erin Price, Susan Rafte, Lorenzo Cohen
Purpose The Society for Integrative Oncology (SIO) produced an evidence-based guideline on use of integrative therapies during and after breast cancer treatment that was determined to be relevant to the American Society of Clinical Oncology (ASCO) membership. ASCO considered the guideline for endorsement. Methods The SIO guideline addressed the use of integrative therapies for the management of symptoms and adverse effects, such as anxiety and stress, mood disorders, fatigue, quality of life, chemotherapy-induced nausea and vomiting, lymphedema, chemotherapy-induced peripheral neuropathy, pain, and sleep disturbance...
June 11, 2018: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/29887785/physical-activity-exercise-and-breast-cancer-what-is-the-evidence-for-rehabilitation-aftercare-and-survival-a-review
#9
REVIEW
Petra Wirtz, Freerk T Baumann
The current scientific field of exercise interventions in breast cancer is very large. Rehabilitation focuses on restoring or improving quality of life and thus on independence and participation in life. Hence, it is important to investigate exercise interventions in the setting of rehabilitation and aftercare. It is also necessary to determine the influence of physical activity or exercise therapy on the prevention of recurrence and mortality as well as on certain side effects of the disease and its medical treatment in rehabilitation...
April 2018: Breast Care
https://www.readbyqxmd.com/read/29875415/the-benefits-of-modified-folfirinox-for-advanced-pancreatic-cancer-and-its-induced-adverse-events-a-systematic-review-and-meta-analysis
#10
Hongxuan Tong, Zhu Fan, Biyuan Liu, Tao Lu
FOLFIRINOX has been one of the first-line options for advanced pancreatic cancer, even though it induces significant adverse effects. Several institutions have begun using modified FOLFIRINOX to decrease its side effects and increase its tolerability. We systematically investigated the outcome from patients who initially received modified FOLFIRINOX as a chemotherapy regimen for advanced pancreatic cancer. We used the random-model generic inverse variance method to analyse the binary data with 95% confidence intervals (CIs)...
June 6, 2018: Scientific Reports
https://www.readbyqxmd.com/read/29873695/platinum-based-neoadjuvant-chemotherapy-in-triple-negative-breast-cancer-a-systematic-review-and-meta-analysis
#11
F Poggio, M Bruzzone, M Ceppi, N F Pondé, G La Valle, L Del Mastro, E de Azambuja, M Lambertini
Background: The role of platinum-based neoadjuvant chemotherapy in triple-negative breast cancer (TNBC) patients is highly controversial and it is not endorsed by current guidelines. Our meta-analysis aimed to better elucidate its activity, efficacy and safety. Material and methods: A systematic search of Medline, Web of Science and conferences proceedings up to 30 October 2017 was carried out to identify randomized controlled trials (RCTs) investigating platinum-based versus platinum-free neoadjuvant chemotherapy in TNBC patients...
June 4, 2018: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/29873180/longitudinal-validation-and-comparison-of-the-chinese-version-of-the-european-organization-for-research-and-treatment-of-cancer-quality-of-life-chemotherapy-induced-peripheral-neuropathy-questionnaire-eortc-qlq-cipn20-and-the-functional-assessment-of-cancer
#12
Hui Lin Cheng, Alex Molassiotis
AIM: To validate and compare the Chinese version of the European Organization for Research and Treatment of Cancer Quality of Life-Chemotherapy-Induced Peripheral Neuropathy Questionnaire (EORTC QLQ-CIPN20) and the Functional Assessment of Cancer-Gynecologic Oncology Group-Neurotoxicity subscale (FACT/GOG-Ntx) for measuring chemotherapy-induced peripheral neuropathy (CIPN) in cancer patients. METHODS: Patients were assessed with the EORTC QLQ-CIPN20, FACT/GOG-Ntx, National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) and World Health Organization criterion of CIPN (WHO-CIPN) from baseline up to 10 assessment points...
June 5, 2018: Asia-Pacific Journal of Clinical Oncology
https://www.readbyqxmd.com/read/29866790/the-influence-of-nicotine-on-lung-tumor-growth-cancer-chemotherapy-and-chemotherapy-induced-peripheral-neuropathy
#13
S Lauren Kyte, David A Gewirtz
Studies in animal models have suggested that nicotine, an agonist of nicotinic acetylcholine receptors (nAChRs), may have the potential to prevent and/or reverse the peripheral neuropathy induced by cancer chemotherapeutic drugs, such as paclitaxel and oxaliplatin. However, a large body of evidence suggests that nicotine may also stimulate lung tumor growth and/or interfere with the effectiveness of cancer chemotherapy. While the reported proliferative effects of nicotine are highly variable, the antagonism of antitumor drug efficacy is more consistent, although this latter effect has been demonstrated primarily in cell culture studies...
June 4, 2018: Journal of Pharmacology and Experimental Therapeutics
https://www.readbyqxmd.com/read/29864986/chronic-neuropathic-pain-following-oxaliplatin-and-docetaxel-a-5-year-follow-up-questionnaire-study
#14
K J Bennedsgaard, L Ventzel, A B Jensen, A R Jensen, H Tankisi, N B Finnerup
Background Adjuvant chemotherapy with docetaxel and oxaliplatin increases survival in patients with high-risk breast and colorectal cancer, respectively, but may induce acute and chronic neurotoxicity. This study is a 5-year follow-up of chronic chemotherapy-induced peripheral neuropathy (CIPN). Methods In 2011-2012, 74 patients with high-risk colorectal cancer and 100 patients with high-risk breast cancer answered a questionnaire before, during and one year after receiving adjuvant chemotherapy with oxaliplatin and docetaxel, respectively...
December 29, 2017: Scandinavian Journal of Pain
https://www.readbyqxmd.com/read/29862996/sigma-1-receptor-a-new-player-in-neuroprotection-against-chemotherapy-induced-peripheral-neuropathy
#15
Jordi Bruna, Roser Velasco
Chemotherapy-induced peripheral neuropathy is a very frequent neurological complication in cancer. Oxaliplatin (OXA) is a platinum analogue used as a first-line agent in the treatment of colorectal cancer. OXA induced peripheral neuropathy (OIN) is the main toxicity both during and after the completion of chemotherapy that presents as two distinct syndromes: acute and chronic neuropathy. None of the neuroprotective agents previously tested had prevented or limited the acute and/or chronic OIN. MR309 (previously developed as E-52862) is a novel selective sigma-1 receptor (S1R) antagonist with preclinical analgesic activity in OXA-induced neuropathic pain in animal models...
May 2018: Neural Regeneration Research
https://www.readbyqxmd.com/read/29861308/persistent-chemotherapy-induced-peripheral-neuropathy-are-dose-reductions-and-drug-modifications-our-only-options
#16
EDITORIAL
Heidi S Donovan, Grace B Campbell
No abstract text is available yet for this article.
June 2018: Gynecologic Oncology
https://www.readbyqxmd.com/read/29859720/diffusion-weighted-imaging-changes-in-a-child-with-posterior-ischemic-optic-neuropathy
#17
Dana B Harrar, Jessica Solomon, Ankoor S Shah, Jennifer Vaughn, Adam D Durbin, Michael J Rivkin
BACKGROUND: Posterior ischemic optic neuropathy results from ischemia of the retrobulbar aspect of the optic nerve. It presents as acute loss of vision without optic disc swelling. This is rare in children, with only seven cases reported to date. Neuroimaging is frequently used to aid in the diagnosis of acute visual complaints in children; however, none of the cases described to date delineate the neuroimaging findings of this entity in children. METHODS: The method used is a retrospective review of the electronic medical record...
April 4, 2018: Pediatric Neurology
https://www.readbyqxmd.com/read/29848697/ampakines-attenuate-staurosporine-induced-cell-death-in-primary-cortical-neurons-implications-in-the-chemo-brain-phenomenon
#18
Daniel P Radin, Gary A Rogers, Kimberley E Hewitt, Richard Purcell, Arnold Lippa
BACKGROUND/AIM: Mounting evidence suggests that trophic cell signaling can be mediated by alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPAR) activation. It has been demonstrated that exogenous application of brain-derived neurotrophic factor (BDNF) is highly neuroprotective in vitro against neurotoxic insults such as standard chemotherapies. MATERIALS AND METHODS: Because positive allosteric modulation of AMPARs with ampakines can increase both BDNF mRNA and protein in vitro and in vivo, we examined whether application of the ampakines CX614 and CX729 promoted neuroprotection against staurosporine-induced cell death in rat primary cortical neurons using propidium iodide to stain for dead cells...
June 2018: Anticancer Research
https://www.readbyqxmd.com/read/29846765/gemcitabine-plus-nab-paclitaxel-vs-folfirinox-for-patients-with-advanced-pancreatic-cancer
#19
Junko Tahara, Kyoko Shimizu, Nao Otsuka, Junichi Akao, Yukiko Takayama, Katsutoshi Tokushige
PURPOSE: New chemotherapies have become available for the treatment of advanced pancreatic cancer and have led to changes in its standard treatments. Since pancreatic cancer is becoming more common as a result of population aging, there is a need for diversification of chemotherapy. METHODS: Between March 2014 and April 2017, FOLFIRINOX (FFX) or gemcitabine plus nab-paclitaxel (G-nab) was used as first-line therapy to treat 27 patients with locally advanced and metastatic pancreatic cancer at our hospital...
May 30, 2018: Cancer Chemotherapy and Pharmacology
https://www.readbyqxmd.com/read/29805744/oxaliplatin-induced-blood-brain-barrier-loosening-a-new-point-of-view-on-chemotherapy-induced-neurotoxicity
#20
Jacopo Junio Valerio Branca, Mario Maresca, Gabriele Morucci, Matteo Becatti, Ferdinando Paternostro, Massimo Gulisano, Carla Ghelardini, Daniela Salvemini, Lorenzo Di Cesare Mannelli, Alessandra Pacini
Oxaliplatin is a key drug in the treatment of advanced metastatic colorectal cancer. Despite its beneficial effects in tumor reduction, the most prevalent side-effect of oxaliplatin treatment is a chemotherapy-induced neuropathy that frequently forces to discontinue the therapy. Indeed, along with direct damage to peripheral nerves, the chemotherapy-related neurotoxicity involves also the central nervous system (CNS) as demonstrated by pain chronicity and cognitive impairment (also known as chemobrain), a newly described pharmacological side effect...
May 4, 2018: Oncotarget
keyword
keyword
70500
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"